Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574834 · ClinicalTrials.gov registry record · Early Phase 1
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT00574834 is a Early Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 17 participants.
The verdict
NCT00574834, a Early Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance.
Interventions
- DRUG Ramipril
- DRUG HCTZ-hydrochlorothiazide
- DRUG Ramipril+HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-03 |
| Est. Completion | 2014-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574834
The ClinicalTrials.gov registry entry for NCT00574834 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ramipril is the first listed.
NCT00574834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574834 about?
NCT00574834 is a clinical study titled "Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes". The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose tolerance. Hypothesis - Ramipril effects will delay the onset of type 2 diab...
What is the current status of trial NCT00574834?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2007-03. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00574834?
The interventions under investigation include: Ramipril (DRUG), HCTZ-hydrochlorothiazide (DRUG), Ramipril+HCTZ (DRUG).
Who is sponsoring clinical trial NCT00574834?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.